RADNOR -
The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 74,650 shares of its common stock (the 'Common Stock') and the grant of restricted stock units which, upon vesting, are equivalent in aggregate to 2,500 shares of the Company's common stock as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(4).
These stock option grants have an exercise price of
About
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY (ganaxolone) oral suspension CV in the
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as 'may', 'will', 'expect', 'anticipate', 'estimate', 'intend', 'believe', and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements.
Contact:
Email: jdenike@marinuspharma.com
Email: mcameron@marinuspharma.com
(C) 2023 Electronic News Publishing, source